Plain-English translation of NCT06747858 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Cystic Fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , which is inhaled daily like a nebulizer treatment, to see if it can help people with cystic fibrosis who are not currently on standard CFTR modulator therapy. Researchers want to learn whether the medication is safe, well-tolerated, and effective at improving lung function in these patients. The study will test three different dose levels in smaller groups before moving to a longer 12-week treatment period.
Not all people with cystic fibrosis can benefit from or tolerate current standard treatments — some may be allergic, unable to access them, or find they don't work well enough. This trial is exploring whether this new medication could offer help to those patients.
You likely qualify if…
You likely don't qualify if…
You will inhale the medication daily using a nebulizer machine, similar to treatments you may already use. Depending on which group you're assigned to, you'll either take the medication for 4 weeks followed by 8 weeks of safety monitoring, or for 12 weeks followed by an additional 12 weeks of monitoring. Throughout the study, you'll visit the clinic regularly so researchers can check your lung function, take blood samples, and monitor how you're responding to the treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States